PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Landmark study investigates potential of Ambroxol, a cough medicine, to slow Parkinson’s-related dementia

Researchers at Lawson Research Institute are studying Ambroxol - a common cough medicine in Europe - as a potential treatment for dementia linked to Parkinson’s disease

2025-06-30
(Press-News.org) LONDON, Ont. – Dementia poses a major health challenge with no safe, affordable treatments to slow its progression.

Researchers at Lawson Research Institute (Lawson), the research arm of St. Joseph’s Health Care London, are investigating whether Ambroxol - a cough medicine used safely for decades in Europe - can slow dementia in people with Parkinson’s disease.

Published today in the prestigious JAMA Neurology, this 12-month clinical trial involving 55 participants with Parkinson’s disease dementia (PDD) monitored memory, psychiatric symptoms and GFAP, a blood marker linked to brain damage. Parkinson’s disease dementia causes memory loss, confusion, hallucinations and mood changes. About half of those diagnosed with Parkinson’s develop dementia within 10 years, profoundly affecting patients, families and the health care system.

Led by Cognitive Neurologist Dr. Stephen Pasternak, the study gave one group daily Ambroxol while the other group received a placebo. “Our goal was to change the course of Parkinson’s dementia,” says Pasternak. “This early trial offers hope and provides a strong foundation for larger studies.”

Key findings from the clinical trial include:

• Ambroxol was safe, well-tolerated and reached therapeutic levels in the brain

• Psychiatric symptoms worsened in the placebo group but remained stable in those taking Ambroxol.

• Participants with high-risk GBA1 gene variants showed improved cognitive performance on Ambroxol

 • A marker of brain cell damage (GFAP) increased in the placebo group but stayed stable with Ambroxol, suggesting potential brain protection.

Although Ambroxol is approved in Europe for treating respiratory conditions and has a long-standing safety record - including use at high doses and during pregnancy - it is not approved for any use in Canada or the U.S.

“Current therapies for Parkinson’s disease and dementia address symptoms but do not stop the underlying disease,” explains Pasternak. “These findings suggest Ambroxol may protect brain function, especially in those genetically at risk. It offers a promising new treatment avenue where few currently exist.”

Ambroxol supports a key enzyme called glucocerebrosidase (GCase), which is produced by the GBA1 gene. In people with Parkinson’s disease, GCase levels are often low. When this enzyme doesn’t work properly, waste builds up in brain cells, leading to damage. Pasternak learned about Ambroxol during a fellowship at The Hospital for Sick Children (SickKids) in Toronto, where it was identified as a treatment for Gaucher disease - a rare genetic disorder in children caused by a deficiency of GCase.

He is now applying that research to explore whether boosting GCase with Ambroxol could help protect the brain in Parkinson’s-related diseases. “This research is vital because Parkinson’s dementia profoundly affects patients and families,” says Pasternak. “If a drug like Ambroxol can help, it could offer real hope and improve lives.”

Funded by the Weston Foundation, this study is an important step toward developing new treatments for Parkinson’s disease and other cognitive disorders, including dementia with Lewy bodies. Pasternak and his team plan to start a follow-up clinical trial focused specifically on cognition later this year.

Dr. Stephen Pasternak is available for interviews on June 30.

To arrange, please contact: Allison Hansen, Communication Consultant St. Joseph’s Health Care London Cell: 519-933-4272 or 519-646-6100 ext. 61501 allison.hansen@sjhc.london.on.ca

About Lawson Research Institute: Lawson Research Institute, the health innovation arm of St. Joseph's Health Care London, is committed to making and sharing discoveries that improve lives locally and internationally. Every day, Lawson researchers work to transform imagination to innovation to patient impact. Lawson leads health-care research. Find us online at sjhc.london.on.ca/research and on social media @stjosephslondon

END


ELSE PRESS RELEASES FROM THIS DATE:

Finding suggests treatment approach for autoimmune diseases

2025-06-30
An engineered protein turns off the kind of immune cells most likely to damage tissue as part of Type-1 diabetes, hepatitis, multiple sclerosis, shows a new study in mice.   In these autoimmune diseases, T cells mistakenly target the body’s own tissues instead of invading viruses or bacteria as they would during normal immune responses. Treatments focused on T cells have been elusive because blocking their action broadly weakens the immune system and creates risk for infections and cancer. Published online June 30 in the journal Cell, the study revealed that holding closely together two protein groups (signaling complexes) on ...

A new “link” to triple-negative breast cancer

2025-06-30
Breast cancer is one of the most common cancers among women in the United States. Thanks to decades of fundamental research, it’s also one of the most curable. The exception is a particularly aggressive variant known as triple-negative breast cancer (TNBC). It accounts for 10 to 15 percent of all breast cancer cases. It disproportionately affects younger and African American women. No effective therapies exist. A new discovery by Cold Spring Harbor Laboratory Professor David Spector and graduate student Wenbo Xu—published in Molecular Cancer Research, a journal of the American Association for Cancer Research—could help ...

Cool is cool wherever you are

2025-06-30
From Chile to China, cultures vary greatly around the globe, but people in at least a dozen countries agree about what it means to be cool, according to research published by the American Psychological Association.    The researchers conducted experiments with almost 6,000 participants from countries around the world and found that cool people have surprisingly similar personalities. Even though Eastern and Western cultures often differ in many cultural attitudes, cool people were universally perceived to be more extraverted, hedonistic, powerful, adventurous, open and autonomous.  “Everyone wants to be cool, or at least ...

Meteorological satellites observe temperatures on Venus

2025-06-30
Imaging data from Japan’s Himawari-8 and -9 meteorological satellites have been successfully used to monitor temporal changes in Venus’ cloud-top temperature, revealing unseen patterns in the temperature structure of various waves. A team led by the University of Tokyo collated infrared images from 2015–25 to estimate brightness temperatures on day to year scales. The results demonstrate that meteorological satellites can serve as additional eyes to access the Venusian atmosphere from space ...

New hope for brain cancer: FAU awarded grants for glioblastoma treatment

2025-06-30
Florida Atlantic University researchers have secured two key grants to investigate targeting a gene for the first time as a new approach to treat glioblastoma, a very aggressive and fast-growing type of brain cancer.   Malignant gliomas, such as glioblastoma multiforme and astrocytomas, are the most common type of primary brain tumor in the United States. They make up about 78% of all malignant brain tumors. Although these tumors are not very common, especially in the U.S., they cause a high number of cancer deaths because they are so aggressive. These awards, granted by the Florida Department of Health’s Cancer Connect program for $562,000 and the Palm Health Foundation for ...

AI for Good Global Summit 2025 - Exclusive press tour (ITU/United Nations)

2025-06-30
The United Nations' digital tech agency, ITU, invites reporters to an exclusive press tour on Monday, 7 July, before the official opening of the AI for Good Global Summit 2025. With the rapid advance of artificial intelligence – from autonomous AI agents to brain-machine interfaces, self-driving vehicles, and a growing range of quantum technologies – AI for Good highlights global AI action to safeguard the future.​ AI for Good will feature talks from AI leaders and 100+ demos showcasing AI innovations to deliver ...

Bacteria hijack tick cell defenses to spread disease

2025-06-30
PULLMAN, Wash. – Washington State University researchers have discovered how the bacteria that cause anaplasmosis and Lyme disease hijack cellular processes in ticks to ensure their survival and spread to new hosts, including humans. Based in the College of Veterinary Medicine, the team found that the bacteria can manipulate a protein known as ATF6, which helps cells detect and respond to infection, to support its own growth and survival inside the tick. The findings, published in the journal Proceedings of the National Academy of Sciences, could serve as a launching point for developing methods to eliminate the bacteria in ticks before they are transmitted to humans and ...

New study shows omega-6 does not increase inflammation

2025-06-30
June 30, 2025, Sioux Falls, SD: A new study published in Nutrients offers new insight into omega-6 and whether it is truly the proinflammatory fatty acid many claim it to be.   There is currently a heightened interest in the health effects of seed oils, many of which are rich in linoleic acid (LA), an essential omega-6 fatty acid. Many have claimed that western diets contain “too much” LA and that many diseases of modernity stem from the increased intake of LA over the last century.   This narrative places the blame on excess inflammation presumably caused by higher LA intakes. But ...

Firms raise the bar after missing the target: Strategic use of overestimated earnings targets

2025-06-30
When companies miss their earnings targets, one might expect them to lower expectations and rebuild investor trust slowly. However, many do the opposite. They announced even higher goals for the next period. A team of researchers, led by Professor Jungwon Min from Inha University, South Korea, including Professor Hyonok Kim from Tokyo Keizai University and Professor Konari Uchida from the Graduate School of Business and Finance, Waseda University, Japan, published a new study online in the journal Review of Managerial Science on June 03, 2025. It uncovers how firms strategically ...

Pusan National University scientists uncover gene mutation tied to poor outcomes in transplant patients

2025-06-30
Organ transplantation has significantly revolutionized the treatment of patients with organ failure. However, the recipient’s immune system recognizes transplanted organs as foreign and elicits a defensive response that can lead to serious complications. Bronchiolitis obliterans syndrome (BOS) is one such complication that arises frequently following lung transplantation (LT) and hematopoietic stem cell transplantation (HSCT). BOS is characterized by the narrowing of airways, fibrosis, and inflammation in the lung tissue leading to breathing difficulties and poor graft survival.    Immune mechanisms and shared pathological ...

LAST 30 PRESS RELEASES:

Study unexpectedly finds living in rural, rather than urban environments in first five years of life could be a risk factor for developing type 1 diabetes

Editorial urges deeper focus on heart-lung interactions in pulmonary vascular disease

Five University of Tennessee faculty receive Fulbright Awards

5 advances to protect water sources, availability

OU Scholar awarded Fulbright for Soviet cinema research

Brain might become target of new type 1 diabetes treatments

‘Shore Wars:’ New research aims to resolve coastal conflict between oysters and mangroves, aiding restoration efforts

Why do symptoms linger in some people after an infection? A conversation on post-acute infection syndromes

Study reveals hidden drivers of asthma flare-ups in children

Physicists decode mysterious membrane behavior

New insights about brain receptor may pave way for next-gen mental health drugs

Melanoma ‘sat-nav’ discovery could help curb metastasis

When immune commanders misfire: new insights into rheumatoid arthritis inflammation

SFU researchers develop a new tool that brings blender-like lighting control to any photograph

Pups in tow, Yellowstone-area wolves trek long distances to stay near prey

AI breakthrough unlocks 'new' materials to replace lithium-ion batteries

Making molecules make sense: A regional explanation method reveals structure–property relationships

Partisan hostility, not just policy, drives U.S. protests

The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: August 1, 2025

Young human blood serum factors show potential to rejuvenate skin through bone marrow

Large language models reshape the future of task planning

Narrower coverage of MS drugs tied to higher relapse risk

Researchers harness AI-powered protein design to enhance T-cell based immunotherapies

Smartphone engagement during school hours among US youths

Online reviews of health care facilities

MS may begin far earlier than previously thought

New AI tool learns to read medical images with far less data

Announcing XPRIZE Healthspan as Tier 5 Sponsor of ARDD 2025

Announcing Immortal Dragons as Tier 4 Sponsor of ARDD 2025

Reporting guideline for chatbot health advice studies

[Press-News.org] Landmark study investigates potential of Ambroxol, a cough medicine, to slow Parkinson’s-related dementia
Researchers at Lawson Research Institute are studying Ambroxol - a common cough medicine in Europe - as a potential treatment for dementia linked to Parkinson’s disease